Questcor Expansion Strategy Pays Off For Acthar
This article was originally published in The Pink Sheet Daily
Executive Summary
Questcor has successfully revived a decades-old product by raising the drug’s price, securing a new approval in a niche orphan indication in infants and making a commercial push in areas like multiple sclerosis and rheumatoid arthritis.
You may also be interested in...
At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them
Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.
Payer Pushback Underpins Mallinckrodt's Disappointing Q3 Results
Mallinckrodt's high-priced H.P Acthar Gel was under pressure in the third quarter, which management attributed to payer complexities. The issue is broader than just Acthar, firm says.
Mallinckrodt Vision For Growth Emphasizes Acthar, Ofirmev
The specialty pharma laid out plans for driving future growth after completing two acquisitions earlier this year. Two of the key drivers will be drugs acquired in those deals – along with more business development.